OncoMatch/Clinical Trials/NCT06176729
Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
Is NCT06176729 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Polatuzumab Vedotin, Rituximab, Lenalidomide for diffuse large b cell lymphoma.
Treatment: Polatuzumab Vedotin, Rituximab, Lenalidomide — This is a prospective, single-arm, phase II study, and the purpose of this study is to evaluate the efficacy and safety of Pola-R2 regimen in newly diagnosed elderly diffuse large B cell lymphoma classified into un-fit or frail group by comprehensive geriatric assessment(CGA).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Demographics
Prior therapy
Lab requirements
Blood counts
adequate bone marrow reserve
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate organ function and adequate bone marrow reserve
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06176729 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify